ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1.7 | 0.1 | 0.0 |
| Total income | 1.7 | 0.1 | 0.0 |
| Profit before exceptional items & tax | -0.0 | -5.3 | -0.0 |
| Profit before tax | -0.0 | -5.3 | -0.0 |
| Net profit | -0.0 | -5.3 | -0.0 |
| Operating margin | 0.0% | n/m | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, BSE: 519353. Figures extracted from the filing.
Bansisons Tea Industries Ltd: key numbers
- Share price
- ₹7.68
- Market cap
- ₹4.86 Cr
- Revenue (annual)
- ₹0.10 Cr
- Net profit (annual)
- ₹-5.37 Cr
- P/E (TTM)
- -0.9×Sector 29.0×
- Promoter holding
- 23.15%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bansisons Tea Industries Ltd
All →Novyra Pharmachem Q2 FY27 Results: Net Profit ₹0 Cr
Novyra Pharmachem Ltd reported revenue from operations of ₹4.2 Cr and net profit of ₹0 Cr for Q2 FY27.
- Key figure
- Net profit ₹0 Cr
Novyra Pharmachem Board Meeting Date
Novyra Pharmachem will hold a board meeting on 2 November 2026 to consider unaudited Q2 results. Agenda items remain proposed until the meeting.
Novyra Pharmachem Other Announcement
Novyra Pharmachem Ltd filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Novyra Pharmachem Other Announcement
Novyra Pharmachem intimated BSE of a change in its official email ID under Reg 30. The update is purely administrative with no business or financial impact.
Bansisons Tea Industries Other Announcement
The company has officially changed its name from Bansisons Tea Industries Limited to Novyra Pharmachem Limited. This change reflects the company's expansion into the pharmaceutical sector.
Bansisons Tea Industries Board Meeting Date
Novyra Pharmachem Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.